BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Boehringer Ingelheim
Medtronic
Argus Health
Cantor Fitzgerald
Cipla
Express Scripts
Novartis
AstraZeneca
Harvard Business School

Generated: January 18, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,922,736

« Back to Dashboard

Summary for Patent: 5,922,736
Title: Chronic, bolus administration of D-threo methylphenidate
Abstract:Chronic bolus administration of D-threo methylphenidate is provided. The administration of the D-threo isomer eliminates adverse side effects associated with the DL racemate, and provides improved effectiveness. The compositions and methods of the invention are useful in treating nervous system disorders including attention deficit disorder, attention deficit hyperactivity disorder, and cognitive decline associated with systemic diseases such as acquired immunodeficiency syndrome.
Inventor(s): Dariani; Maghsoud M. (Fanwood, NJ), Zeitlin; Andrew L. (Millington, NJ), Zeldis; Jerome B. (Princeton, NJ)
Assignee: Celegene Corporation (Warren, NJ)
Application Number:08/937,684
Patent Claim Types:
see list of patent claims
Use; Delivery; Composition;

Drugs Protected by US Patent 5,922,736

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 5,922,736

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Portugal 1032389 ➤ Subscribe
New Zealand 530211 ➤ Subscribe
New Zealand 565754 ➤ Subscribe
Mexico PA04000249 ➤ Subscribe
New Zealand 503571 ➤ Subscribe
South Korea 20040029360 ➤ Subscribe
Japan 2005520780 ➤ Subscribe
Japan 2002510318 ➤ Subscribe
Japan 5412700 ➤ Subscribe
Japan 2010265299 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Merck
Baxter
Citi
Moodys
Teva
Farmers Insurance
Johnson and Johnson
Dow
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot